CCN1 and breast carcinoma: Targeting CYR61 directly by using agents such as the monoclonal antibody, 093G9 has shown promise in preclinical models, in which it inhibited the proliferation, migration, and metastasis of breast cancer cells by downregulating AKT and ERK phosphorylation [54].